Beyond Cancer's UNO Therapy Shows Early Promise in Phase 1 Trial
Event summary
- Phase 1 trial of UNO monotherapy in 10 heavily pretreated patients showed early clinical activity and favorable safety profile.
- Seven of ten patients alive 19 to 37 months post-treatment, with two triple-negative breast cancer patients showing no evidence of disease.
- AACR 2026 presentation (April 19) will include updated trial data beyond the published abstract.
- UNO therapy demonstrated limited toxicity with most adverse events Grade 1, and one Grade 3 hypoxia event that resolved fully.
The big picture
Beyond Cancer's UNO therapy represents a novel approach to cancer treatment, leveraging ultra-high concentration nitric oxide to stimulate anti-tumor immune responses. The early Phase 1 results suggest potential as a monotherapy or in combination with existing immunotherapies, addressing the critical challenge of metastatic disease. The company's focus on limited toxicity and single-treatment efficacy could differentiate it in the competitive oncology space, though further clinical validation will be essential.
What we're watching
- Therapeutic Potential
- Whether UNO can establish itself as a differentiated complement to anti-PD-1 therapy in metastatic disease.
- Clinical Development
- The pace at which Beyond Cancer advances UNO into combination therapies or earlier lines of treatment.
- Regulatory Pathway
- How the Phase 1 data positions UNO for future regulatory approvals and commercialization.
Related topics